215 related articles for article (PubMed ID: 29483210)
21. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model.
Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E
J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692
[TBL] [Abstract][Full Text] [Related]
22. Vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum for advanced germ cell testis tumors: Brazilian experience.
Srougi M; Simon SD; de Góes GM
J Urol; 1985 Jul; 134(1):65-9. PubMed ID: 2409300
[TBL] [Abstract][Full Text] [Related]
23. Expression of OCT4 in the primary germ cell tumors and thymoma in the mediastinum.
Jung SM; Chu PH; Shiu TF; Wu HH; Kuo TT; Chu JJ; Lin PJ
Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):273-5. PubMed ID: 16932017
[TBL] [Abstract][Full Text] [Related]
24. Differential expression of SOX2 and SOX17 in testicular germ cell tumors.
Nonaka D
Am J Clin Pathol; 2009 May; 131(5):731-6. PubMed ID: 19369635
[TBL] [Abstract][Full Text] [Related]
25. Poor prognosis of retroperitoneal mixed extragonadal germ cell tumors in an HIV-infected man with severe immunosuppression and bilateral cryptorchidism: a case report.
Li R; Li H
BMC Cancer; 2019 Mar; 19(1):244. PubMed ID: 30885154
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology of male seminomatous and nonseminomatous germ cell tumors and response to first-line chemotherapy from a tertiary cancer center in India.
Joshi A; Zanwar S; Shetty N; Patil V; Noronha V; Bakshi G; Prakash G; Menon S; Prabhash K
Indian J Cancer; 2016; 53(2):313-316. PubMed ID: 28071636
[TBL] [Abstract][Full Text] [Related]
27. Genome-wide expression profiling reveals new insights into pathogenesis and progression of testicular germ cell tumors.
Biermann K; Heukamp LC; Steger K; Zhou H; Franke FE; Sonnack V; Brehm R; Berg J; Bastian PJ; Muller SC; Wang-Eckert L; Buettner R
Cancer Genomics Proteomics; 2007; 4(5):359-67. PubMed ID: 17993720
[TBL] [Abstract][Full Text] [Related]
28. First-line chemotherapy of non-seminomatous germ cell tumors(NSGCTs).
Pliarchopoulou K; Pectasides D
Cancer Treat Rev; 2009 Nov; 35(7):563-9. PubMed ID: 19576697
[TBL] [Abstract][Full Text] [Related]
29. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
30. New Anti-Cancer Strategies in Testicular Germ Cell Tumors.
Chieffi P; De Martino M; Esposito F
Recent Pat Anticancer Drug Discov; 2019; 14(1):53-59. PubMed ID: 30636617
[TBL] [Abstract][Full Text] [Related]
31. Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis.
Houldsworth J; Reuter V; Bosl GJ; Chaganti RS
Cell Growth Differ; 1997 Mar; 8(3):293-9. PubMed ID: 9056671
[TBL] [Abstract][Full Text] [Related]
32. Current Management of Disseminated Germ Cell Tumors.
Lavoie JM; Kollmannsberger CK
Urol Clin North Am; 2019 Aug; 46(3):377-388. PubMed ID: 31277732
[TBL] [Abstract][Full Text] [Related]
33. Apoptosis regulation and spontaneous apoptosis index of testicular germ cell tumors are associated with differentiation and resistance to systemic treatment.
Mandoky L; Szende B; Géczi L; Bodrogi I; Kásler M; Bak M
Anticancer Res; 2008; 28(3A):1641-9. PubMed ID: 18630521
[TBL] [Abstract][Full Text] [Related]
34. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
[TBL] [Abstract][Full Text] [Related]
35. [Observation policy for residual masses after chemotherapy for gonadal and extra-gonadal germ cell tumors].
Takizawa A; Miura T; Fujinami K; Osada Y
Hinyokika Kiyo; 2005 Apr; 51(4):247-51. PubMed ID: 15912783
[TBL] [Abstract][Full Text] [Related]
36. Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.
Sadigh S; Farahani SJ; Shah A; Vaughn D; Lal P
Am J Clin Pathol; 2020 Feb; 153(3):387-395. PubMed ID: 31802108
[TBL] [Abstract][Full Text] [Related]
37. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.
Tryakin A; Fedyanin M; Bulanov A; Kashia S; Kurmukov I; Matveev V; Fainstein I; Gordeeva O; Zakharova T; Tjulandin S
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1817-1823. PubMed ID: 29974210
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
Adra N; Einhorn LH; Althouse SK; Ammakkanavar NR; Musapatika D; Albany C; Vaughn D; Hanna NH
Ann Oncol; 2018 Jan; 29(1):209-214. PubMed ID: 29045540
[TBL] [Abstract][Full Text] [Related]
39. EPCAM-A novel molecular target for the treatment of pediatric and adult germ cell tumors.
Schönberger S; Okpanyi V; Calaminus G; Heikaus S; Leuschner I; Nicholson JC; Stoecklein NH; Schneider DT; Borkhardt A
Genes Chromosomes Cancer; 2013 Jan; 52(1):24-32. PubMed ID: 22987628
[TBL] [Abstract][Full Text] [Related]
40. Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases.
Balzer BL; Ulbright TM
Am J Surg Pathol; 2006 Jul; 30(7):858-65. PubMed ID: 16819328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
